Squats And Planks For BP Lowering; DCBs Compared Head To Head; GLP-1s For HFpEF?
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

A roundup published October 6 highlighted research on isometric exercise, peripheral artery drug-coated balloons and semaglutide for obesity-associated HFpEF. The exercise study reported short-term blood pressure benefits with training three times weekly; the small balloon trial found a measure of endothelial function improved with sirolimus, but 12-month patency and repeat-treatment rates did not materially differ. The HFpEF finding came from preclinical research, not a clinical treatment trial.

A cardiovascular research roundup published by MedPage Today on October 6, 2026, highlighted three findings with different levels of clinical relevance: a randomized study of isometric exercise for blood pressure, a small comparison of two drug-coated balloons for peripheral artery disease, and preclinical research on semaglutide in obesity-associated heart failure with preserved ejection fraction (HFpEF). The results are not equivalent: the exercise and balloon reports describe human research, while the semaglutide finding is from a preclinical study and does not establish a treatment benefit in patients.

The roundup said a randomized study found that isometric training, including squats and planks, produced short-term blood pressure-lowering benefits when done three times a week. The report did not provide the size of the blood pressure change, the number of participants, or how long the benefit lasted. It also did not establish that this schedule is suitable for every person or a replacement for prescribed blood pressure treatment.

A small trial of sirolimus- and paclitaxel-eluting drug-coated balloons examined endovascular treatment for severe peripheral artery disease. According to the roundup, sirolimus performed better on endothelial function, a measure related to the inner lining of blood vessels. That difference did not translate into a material difference in 12-month vessel patency or target lesion revascularization, meaning a repeat procedure to treat the target area.

The third finding concerned semaglutide, sold as Ozempic and Wegovy, as a possible approach to obesity-associated cardiometabolic HFpEF. The roundup characterized the evidence as preclinical and said the study suggested the drug was plausible for reversing disease-related changes. This is an early research signal, not proof that semaglutide reverses HFpEF or improves outcomes in people with the condition.

At a glance
reportWhen: Published October 6, 2026; studies span…
The developmentMedPage Today published an October 6 roundup of cardiovascular research, including findings on exercise frequency, a small head-to-head drug-coated balloon study and preclinical semaglutide research in HFpEF.

What the Three Findings Can Tell Patients

The three reports illustrate why the type and stage of evidence matter when interpreting cardiovascular headlines. A short-term blood pressure result may inform exercise research, but readers need the size and duration of the effect, alongside information about participants, before judging its practical importance. The reported three-times-weekly schedule is a study finding, not a universal prescription.

For people treated for severe leg artery disease, the balloon comparison separates a biological measurement from outcomes that may matter more directly in care. Sirolimus was associated with a better endothelial-function result, but the roundup reported no material difference in patency or repeat treatment at 12 months. The results do not establish one balloon as clinically superior on those outcomes.

The HFpEF work may help motivate further research into obesity-related heart disease, but it is the least ready for direct clinical application. Preclinical findings do not show that a drug works in patients. Taken together, the items are useful as research updates, not as a basis for changing medication, procedures or exercise plans without clinical advice.

Products Worth Considering

Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor

Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor

Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White

Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White

As an affiliate, we earn on qualifying purchases.

Three Studies at Different Stages

The source is a short cardiology research roundup, not a single trial report. It also noted findings on diet guidance, atrial fibrillation and left atrial appendage closure, CT-based aortic valve calcium measurement, coronary intervention and other cardiovascular topics. Those items provide breadth, but the roundup’s brief descriptions do not offer enough detail to compare their methods or strength of evidence directly.

The three studies featured here address different questions. The exercise research tested a training approach and frequency; the balloon trial compared two drug coatings during treatment of peripheral artery disease; and the semaglutide study explored a potential mechanism or effect before clinical testing. Their endpoints also differ: blood pressure, endothelial function and preclinical disease findings should not be treated as interchangeable measures of patient benefit.

“Isometric exercise training — such as squats and plank exercises — was best done three times a week for short-term blood pressure-lowering benefits.”

— MedPage Today roundup, citing the randomized exercise study

Evidence Gaps Before Clinical Decisions

The roundup does not provide the sample sizes, numerical results, participant characteristics or detailed methods for the three highlighted studies. For the exercise research, the size and persistence of the blood pressure change are not stated, nor is it clear from the summary how the three-times-weekly schedule compared with other frequencies. The information supplied also does not establish whether the findings apply across different ages, health conditions or exercise abilities.

For the balloon comparison, the report gives no trial size or confidence intervals, and it does not specify whether differences emerged in other outcomes or patient groups. A small study can be limited in its ability to detect differences, so the reported absence of a material change in two outcomes should not be read as proof that the treatments are identical.

For semaglutide, the underlying experiments and next clinical steps are not detailed. Whether the preclinical finding translates to people remains unknown, including whether any effect would improve symptoms, hospitalizations or survival. The roundup alone also does not support conclusions about the drug’s safety or use specifically for HFpEF.

What Further Research Must Establish

More complete publication details and follow-up research will be needed to show how large and durable the reported blood pressure benefit is, and which people are likely to benefit from isometric training. Until those details are available, people with cardiovascular conditions should discuss exercise intensity and changes to their routine with a qualified clinician, particularly if they have symptoms or other health concerns.

For drug-coated balloons, larger or longer comparative studies could clarify whether the endothelial-function finding predicts meaningful differences in vessel outcomes or repeat procedures. The current summary supplies only a 12-month comparison and does not establish longer-term results.

The semaglutide finding would need to progress from preclinical work through human studies before it could support treatment decisions for HFpEF. Any future clinical evidence would need to address both benefits and risks in the relevant patient population. For now, the roundup signals areas for research rather than changing established care.

Key Questions

Do squats and planks lower blood pressure?

The roundup reported that a randomized study found short-term blood pressure-lowering benefits from isometric exercise, including squats and planks, performed three times weekly. It did not provide the effect size or show that this schedule is appropriate for everyone. Do not stop or alter prescribed treatment based on this summary.

Did the sirolimus drug-coated balloon outperform the paclitaxel balloon?

In a small trial, the sirolimus-eluting balloon performed better on endothelial function. The roundup said there was no material difference between the devices in vessel patency or target lesion revascularization at 12 months, so it does not establish broad clinical superiority.

Is semaglutide proven to treat HFpEF?

No. The finding cited in the roundup was preclinical. It does not establish that semaglutide reverses HFpEF or improves outcomes in people with the condition.

Should patients change treatment based on this roundup?

No treatment change is supported by the brief summaries alone. Patients should speak with their clinician before changing medication, considering a procedure or adopting a new exercise plan, especially if they have existing cardiovascular or other health conditions.

Source: rss

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

Nursing Home And Executives Agree To Pay $1M For Overbilling Allegations

A reported $1 million settlement between a nursing home, its executives and regulators over alleged overbilling is drawing attention. Details remain unconfirmed.

Novel Immune Modulator Promising In Acute Respiratory Distress Syndrome

A 90-patient phase IIb trial found better day-7 respiratory recovery with inhaled EXO-CD24, but larger studies are needed to confirm benefit.

Abby Care Raises $82M To Train, Pay Family Caregivers

Abby Care raised $82 million in Series C financing to expand its model of training and paying family caregivers for in-home care.

Another Surgical Treatment For Back Pain Fails In Rigorous Analysis

A registry analysis of 2,252 patients found no significant 12-month disability benefit from adding fusion to decompression surgery for spinal stenosis.